BIO vs MSFT Stock Comparison

BIO currently leads MSFT in this stock comparison, with AIQ scores of 73 vs 67. The clearest difference is value, while MSFT has the stronger quality profile.

Market data as of Nov 18, 2026 market close· AIQ score gap 6 points
BIO
Healthcare
vs
MSFT
Technology
BIO
Bio-Rad Laboratories, Inc.
Leads
Price
$370
Day move
+3.34%
AIQ Score
73/100
Best edge
Value
Sector
Healthcare
MSFT
Microsoft Corporation
Price
$508
Day move
+0.4%
AIQ Score
67/100
Best edge
Quality
Sector
Technology

What is the main difference between BIO and MSFT?

BIO leads the current stock comparison as Bio-Rad Laboratories, Inc., with the clearest separation coming from value and the broader AIQ evidence mix.

AlgovestIQ AIQ Comparison

Bio-Rad Laboratories, Inc. vs Microsoft Corporation

Data as of Nov 18, 2026· market close· Cross-sector · Healthcare vs Technology· Coverage 62/66 fields· High confidence
AIQ VerdictFragileAIQ Comparison Conviction 3/10

BIO leads

BIO leads by 6 AIQ points, primarily on Value, and the lead has widened from 3 points over 30 sessions.

Fragile: 2 of 5 evidence groups support BIO, its lead is widening, and its current signal state is conflicted.

Evidence agreement: 2 of 5Comparison trend: Strengthening
BIO

Bio-Rad Laboratories, Inc.

Leads
AIQ Score
73/100
AIQ Edge Score
10/10
MSFT

Microsoft Corporation

AIQ Score
67/100
AIQ Edge Score
8/10

The Algovestiq AIQ Score currently favors BIO over MSFT, 73 versus 67 as of Nov 18, 2026. BIO's advantage is driven primarily by stronger value, while MSFT holds the stronger quality profile. BIO also shows the stronger technical structure relative to its 50-day moving average. 2 of 5 covered evidence groups favor BIO today, and the comparison is rated Fragile on stability: only 2 of 5 covered evidence groups agree. BIO lead: Strengthening — the AIQ differential moved from 3 to 6 points over 30 sessions.

Compare Bio-Rad Laboratories, Inc. and Microsoft Corporation across the Algovestiq AIQ Score, valuation, quality, momentum, risk, technicals and analyst expectations.

Currently unavailable

Performance over time

Total return with distributions reinvested, from daily closes.

BIO
-51.1%
MSFT
+55.6%

Total return comparison

Growth of $10,000, distributions reinvested

BIO $4,886 · MSFT $15,558

Split-adjusted closes; each distribution is reinvested at the close on its ex-dividend date. Taxes and trading costs are not modeled.

Compare BIO and MSFT against another ticker

Open a multi-ticker workspace without changing this focused pair page.

Basic: 2 symbols·Explorer: 3 symbols·Pro and Premium: 5 symbols·Your limit: 2

AIQ Factor Divergence

Where the two separate, on the four dimensions behind the AIQ Score. Bars read outward from a shared zero: further from the centre is a wider gap.

BIO advantage
0
MSFT advantage
  • Value80 vs 52
    BIO +28
  • Quality61 vs 65
    MSFT +4
  • Risk Resilience74 vs 71
    Even
  • Momentum79 vs 77
    Even

2 of 5 evidence groups favor BIO. BIO’s edge is concentrated in value; MSFT keeps a meaningful quality edge.

What changed since the last close

Latest scored session 2026-11-18, compared against the prior scored session 2026-11-17.

BIO0 AIQ

Largest factor move: Momentum -1, not enough on its own to move the overall score.

New signals

  • MACD Bearish Crossover — bearish, momentum, short horizon
  • MACD Histogram Expanding Bearish — bearish, momentum, short horizon
MSFT-1 AIQ

Largest factor move: Momentum -2

No signal started or stopped since the prior session; its 7 active signals are unchanged.

BIO's lead widened by 1 AIQ point in the latest session.

Deeper signal detail for each name lives on its own signals page — BIO and MSFT both carry a full feed there.

The central trade-off

BIO (Bio-Rad Laboratories, Inc.): the stronger current systematic profile, led by value.

MSFT (Microsoft Corporation): the counter-case, on quality, fundamentals — but at materially higher volatility, 36.9% against 31.4%.

Which one fits your objective

The same two names rank differently depending on what you are optimizing for. All six reads are shown at once — none of them is hidden behind a toggle.

Balanced

BIO

BIO on the overall AIQ Score, which weights Quality and Value most heavily.

Growth

BIO

BIO on combined revenue and EPS growth.

Value

BIO

BIO on the peer-relative Value factor, by 28 points.

Momentum

Even

The two are level on Momentum.

Lower downside

BIO

BIO carries the lower 1-month annualized volatility.

Analyst upside

Even

Analyst targets are level or not covered for both names.

AIQ vs Wall Street

Where the systematic read and the analyst consensus line up — and where they do not.

MeasureBIOMSFTNote
Implied upside to target—+24.7%Level
Target dispersion—+48.9%Lower is tighter analyst agreement
ConsensusHoldBuyContext, not a primary driver
Analysts covering358Higher coverage generally improves confidence

Analyst targets are expectations, not predictions. Dispersion matters as much as the midpoint.

AIQ Agreement Matrix

2 of 5 covered evidence groups favor BIO. A wide gap backed by one group is a weaker case than a narrow gap backed by five.

Evidence groupFavorsReading
AIQ ScoreBIO73 vs 67
FundamentalsMSFTon balanceEPS growth 23.3% vs 12.4%; TTM ROE 6% vs 8.1%; gross margin 51.3% vs 67.7%; operating margin 4.6% vs 47.1% — MSFT takes 3 of 4 decided legs, not all of them
ValuationBIOValue 80 vs 52
TechnicalsEvenPrice vs 50-day -0.7% vs -2.1%; vs 200-day 15.6% vs 18.7%
Risk ResilienceEvenRisk Resilience 74 vs 71
Analyst expectationsNot coveredNot covered

✓ agrees with the overall verdict · ✕ points the other way. Groups marked “not covered” lack data on one or both of BIO and MSFT and are excluded from the count.

AIQ Decision Stability

Fragile

The conclusion is sensitive to small changes. Treat the lead as provisional and watch the flip conditions below.

  • The AIQ gap is moderate at 6 points.
  • Only 2 of 5 covered evidence groups agree. (argues the conclusion is provisional)
  • The leader's advantage has been widening. (supports the conclusion holding)
  • The lead has been steady session to session. (supports the conclusion holding)
  • The leader is throwing conflicting signals. (argues the conclusion is provisional)

Stability combines the score gap, how broadly the evidence agrees, how steady the lead has been across daily snapshots, the current signal state on both names, and analyst dispersion on BIO.

How the comparison changed

120 daily snapshots · Jun 1 – Nov 18

BIO lead: Strengthening — the AIQ differential moved from 3 to 6 points over 30 sessions.

Jun 1BIO leads above the line · MSFT leads belowNov 18
Today
BIO +6
73 vs 67
7 sessions ago
BIO +6
75 vs 69
30 sessions ago
BIO +3
72 vs 69
90 sessions ago
BIO +11
73 vs 62

The lead has not changed hands in this window.

AIQ Signal Divergence

Only the signals that bear on the head-to-head. A conflicted name is carrying bullish and bearish rules at the same time — the technical evidence is not pointing one way.

BIOConflicted

3 bullish / 2 bearish / 1 neutral, conflicted

Only BIO

  • ATR Expansion - Breakout Mode — neutral, volatility, short horizon (3.56%)
  • MACD Bearish Crossover — bearish, momentum, short horizon
  • TRIX Bullish Signal — bullish, momentum, short horizon
MSFTConflicted

4 bullish / 1 bearish / 2 neutral, conflicted

Only MSFT

  • Bollinger Band Squeeze — neutral, volatility, short horizon (7.6%)
  • ADX Trend Weakening — neutral, trend, medium horizon
  • OBV Bullish Divergence — bullish, volume, medium horizon (-1.0%)
  • Uptrend Structure Active — bullish, trend, long horizon

Both carry 3 more signals that do not separate them: Golden Cross Active, EMA Ribbon Expansion Bullish, MACD Histogram Expanding Bearish.

BIO leads the comparison while carrying a conflicted signal state, which is one reason the stability rating is not higher.

Price vs model alignment

Whether the latest session's price move confirms what the model did over the same session, or contradicts it.

BIONo material change

Neither the price nor the AIQ Score moved enough in the latest session to confirm or contradict the other (price +3.34%, AIQ 0 points).

MSFTDivergence

Price is up while the AIQ Score moved down 1 points over the same session — price and model disagree (price +0.4%, AIQ -1 points).

What would flip this result

A state, not a forecast. These are the specific, observable changes that would reverse the verdict — not a price prediction.

  1. 1MSFT closes the Value gap — currently 28 points behind, the largest single contributor to BIO's edge.
  2. 2MSFT's Bollinger Band Squeeze turns directional — it is neutral today and would confirm a change in trend.
  3. 3BIO's conflicting signal state resolves bearish — it currently carries 3 bullish and 2 bearish rules at once.
  4. 4A market regime shift would change the factor readings behind both scores; a rotation toward or away from quality, value or momentum could move the result.

The full evidence

Every number behind the verdict. The leader is called above each group so you are not left to solve it from the table.

Fundamentals

MSFT leads on balance
MetricBIOMSFT
Revenue growth (YoY)0.8%8.6%
EPS growth (YoY)23.3%12.4%
Gross margin51.3%67.7%
Operating margin4.6%47.1%
Return on equity (TTM)6%8.1%
Debt to equity0.180.28

Performance

BIO leads 4 of 6 windows
MetricBIOMSFT
1 week (5 sessions)-4%-1.3%
1 month (20 sessions)3.6%-1%
3 months (63 sessions)3.1%9.1%
6 months (126 sessions)48%24.2%
Year to date20.9%8.3%
1 year (252 sessions)11.9%2.5%

Technicals

Split
MetricBIOMSFT
RSI (14)45.448.8
ADX (14)12.917
Price vs 50-day-0.7%-2.1%
Price vs 200-day15.6%18.7%
Volatility (1M, annualized)31.4%36.9%

Risk

Split
MetricBIOMSFT
Beta0.731.02
Sharpe ratio0.470.17
Sortino ratio0.690.26
Max drawdown-27.2%-30.8%
Current drawdown-6.1%-5.7%
Annualized volatility36.2%34%
Value at risk (95%)-3%-2.9%

Straight answers

Each answer is regenerated from the current snapshot, not written once and left to age.

Which is better, BIO or MSFT?

On the Algovestiq AIQ Score, BIO is the stronger of the two as of Nov 18, 2026, scoring 73 against MSFT's 67. The edge comes from value. MSFT is not without a case — it holds the better quality profile, which matters more if that is the objective you are optimizing for. This is a systematic score, not a recommendation: it ranks the two on the same evidence, it does not know your holding period or tax position.

Is BIO or MSFT the better buy right now?

BIO carries the stronger systematic profile as of Nov 18, 2026, and the comparison is rated Fragile — 2 of 5 covered evidence groups agree. A Fragile rating means the conclusion is sensitive: only 2 of 5 covered evidence groups agree. Treat the lead as provisional.

Why does the AIQ Score favor BIO over MSFT?

The composite weights Quality, Value, Momentum and Risk Resilience. BIO leads Value by 28 points; MSFT leads Quality by 4 points. Where the two split, the factor with the larger weight carries the result.

Which has more analyst upside, BIO or MSFT?

Analyst price targets imply not covered upside for BIO and +24.7% for MSFT. The model and the Street agree here, which is a broader base of evidence than either alone. Analyst targets are expectations, not predictions, and dispersion matters as much as the midpoint.

Which is better value, BIO or MSFT?

BIO is the better-valued of the two on the peer-relative Value factor. BIO on the peer-relative Value factor, by 28 points. The Value factor reads valuation relative to sector peers and to the company's own fundamental quality, so it is not the same as simply having the lower multiple.

Which has stronger growth, BIO or MSFT?

BIO on combined revenue and EPS growth. Growth here is measured on reported revenue and earnings, not on forward estimates — it describes what the businesses have delivered, not what the Street expects next.

Which has stronger momentum, BIO or MSFT?

The two are level on Momentum. Momentum is one of the four weighted factors in the AIQ composite. It has documented persistence over three- to twelve-month horizons, which makes it a timing input rather than a reason to hold something indefinitely.

Which is riskier, BIO or MSFT?

BIO is the more resilient of the two, so the other name carries the higher downside risk. BIO carries the lower 1-month annualized volatility. Risk Resilience is a weighted factor in the composite; position sizing usually responds to it more usefully than the buy/avoid decision does.

Is BIO more profitable than MSFT?

MSFT leads on the comparable margin measures — gross margin 51.3% vs 67.7%; operating margin 4.6% vs 47.1%; ttm roe 6% vs 8.1%.

Is BIO's lead over MSFT getting stronger or weaker?

BIO lead: Strengthening — the AIQ differential moved from 3 to 6 points over 30 sessions. This is measured from 120 daily comparison snapshots between 2026-06-01 and 2026-11-18. The lead has not changed hands in that window.

What would change the BIO vs MSFT verdict?

The result is a state, not a forecast, so it changes when the underlying evidence changes. Concretely: MSFT closes the Value gap — currently 28 points behind, the largest single contributor to BIO's edge; MSFT's Bollinger Band Squeeze turns directional — it is neutral today and would confirm a change in trend; BIO's conflicting signal state resolves bearish — it currently carries 3 bullish and 2 bearish rules at once; a market regime shift would change the factor readings behind both scores; a rotation toward or away from quality, value or momentum could move the result.

What do the current signals say about BIO and MSFT?

BIO: 3 bullish / 2 bearish / 1 neutral, conflicted. MSFT: 4 bullish / 1 bearish / 2 neutral, conflicted. A conflicted state means bullish and bearish rules are active on the same name at once — the technical evidence is not pointing one way, and a decision taken on it carries more timing risk. The most decision-relevant rule on BIO is Golden Cross Active (bullish, long horizon). On MSFT it is Golden Cross Active (bullish, long horizon).

Compare BIO and MSFT with others

Continue your research

This page answers which of the two. These answer the questions on either side of it.

How this comparison is scored

The Algovestiq AIQ Score composites four factors — Quality, Value, Momentum and Risk, each carrying a fixed weight. Sentiment is reported separately as SentimentPulse and is not folded into the composite. Scores refresh every trading day, and this page regenerates from the latest snapshot rather than being written once.

The verdict names a leader, states how broadly six independent evidence groups agree, and rates how durable that conclusion is given the score gap, its recent trajectory and the current signal state on both names.

How to use side-by-side comparison →

This comparison is informational and educational, not investment advice. AIQ scores update daily; re-check after earnings, guidance or macro data that materially changes either name’s factor profile.